Study of Moderately Hypofractionated Adaptive Postoperative Radiotherapy for Women With High-Risk Endometrial Cancer

What this Trial Is About

This research investigates moderately hypofractionated adaptive postoperative radiotherapy for women with high-risk endometrial cancer. The study is a single-center, single-arm, prospective trial enrolling 20 patients. The goal is to evaluate treatment safety by measuring acute toxicity and to assess longer-term outcomes such as 3-year failure-free survival, chronic toxicity, quality of life, and treatment costs. Participants receive external beam radiation therapy EBRT using an online adaptive radiotherapy technology targeting the vagina and pelvic lymph nodes. The EBRT dose is 40.05 Gy given over 15 fractions, once daily, five days a week. After EBRT, 3D intracavitary brachytherapy is delivered in 2-3 fractions of 4-6 Gy each, spaced 1-2 days apart. Radiotherapy can be combined with chemotherapy, administered during chemotherapy intervals or after its completion. During treatment, patients undergo weekly blood counts, biochemistry tests every two weeks, and toxicity assessments. Follow-up visits occur at treatment end, 3 months, 6 months, and every 6 months up to 3 years, including medical exams, quality of life assessments, and laboratoryimaging tests. The primary outcome is acute toxicity within 90 days of treatment start, while secondary outcomes include longer-term survival, chronic toxicity, quality of life measures, and treatment costs.

Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer